Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FEMY NASDAQ:LYRA NYSEAMERICAN:VTAK NASDAQ:XAIR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.39+6.8%$0.70$0.31▼$1.80$11.95M-2.642.77 million shs1.22 million shsLYRALyra Therapeutics$6.29-0.6%$7.44$3.81▼$37.50$10.41M0.1711,769 shs65,899 shsVTAKCatheter Precision$2.45-2.0%$3.43$2.36▼$33.06$3.72M-0.793.16 million shs16,646 shsXAIRBeyond Air$2.43+7.5%$2.82$2.02▼$13.52$11.81M0.288.81 million shs512,744 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys+6.84%+4.31%-48.83%-55.91%-65.90%LYRALyra Therapeutics-0.63%-8.18%-13.72%-44.53%-53.13%VTAKCatheter Precision-2.00%-0.81%-24.59%-64.67%-67.92%XAIRBeyond Air+7.52%+9.95%-0.82%-31.70%-68.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFEMYFemasys$0.39+6.8%$0.70$0.31▼$1.80$11.95M-2.642.77 million shs1.22 million shsLYRALyra Therapeutics$6.29-0.6%$7.44$3.81▼$37.50$10.41M0.1711,769 shs65,899 shsVTAKCatheter Precision$2.45-2.0%$3.43$2.36▼$33.06$3.72M-0.793.16 million shs16,646 shsXAIRBeyond Air$2.43+7.5%$2.82$2.02▼$13.52$11.81M0.288.81 million shs512,744 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFEMYFemasys+6.84%+4.31%-48.83%-55.91%-65.90%LYRALyra Therapeutics-0.63%-8.18%-13.72%-44.53%-53.13%VTAKCatheter Precision-2.00%-0.81%-24.59%-64.67%-67.92%XAIRBeyond Air+7.52%+9.95%-0.82%-31.70%-68.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFEMYFemasys 3.00Buy$7.331,770.27% UpsideLYRALyra Therapeutics 2.00Hold$100.001,489.83% UpsideVTAKCatheter Precision 0.00N/AN/AN/AXAIRBeyond Air 3.50Strong Buy$11.00352.67% UpsideCurrent Analyst Ratings BreakdownLatest VTAK, LYRA, XAIR, and FEMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025XAIRBeyond AirD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/14/2025LYRALyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral8/13/2025XAIRBeyond AirD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.008/11/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$12.00 ➝ $8.007/17/2025XAIRBeyond AirD Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/17/2025XAIRBeyond AirD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$11.006/25/2025FEMYFemasysHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFEMYFemasys$1.63M7.84N/AN/A$0.10 per share3.92LYRALyra Therapeutics$1.53M6.74N/AN/A$8.86 per share0.71VTAKCatheter Precision$420K8.69N/AN/A$25.29 per share0.10XAIRBeyond Air$3.70M3.43N/AN/A$3.32 per share0.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFEMYFemasys-$18.82M-$0.86N/AN/AN/A-1,113.72%-713.74%-152.60%11/11/2025 (Estimated)LYRALyra Therapeutics-$93.43M-$29.01N/AN/AN/A-5,043.64%-404.56%-60.06%11/11/2025 (Estimated)VTAKCatheter Precision-$16.64MN/A0.00N/AN/A-3,150.33%-193.63%-72.09%11/12/2025 (Estimated)XAIRBeyond Air-$46.62M-$11.93N/AN/AN/A-880.72%-232.61%-115.92%11/10/2025 (Estimated)Latest VTAK, LYRA, XAIR, and FEMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025LYRALyra Therapeutics-$5.79-$5.51+$0.28-$5.51$0.18 million$0.29 million8/12/2025Q1 2026XAIRBeyond Air-$1.50-$1.53-$0.03-$1.53$1.75 million$1.76 million8/8/2025Q2 2025FEMYFemasys-$0.18-$0.16+$0.02-$0.16$0.80 million$0.41 million6/17/2025Q4 2025XAIRBeyond Air-$2.80-$1.80+$1.00-$0.09$1.39 million$1.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFEMYFemasysN/AN/AN/AN/AN/ALYRALyra TherapeuticsN/AN/AN/AN/AN/AVTAKCatheter PrecisionN/AN/AN/AN/AN/AXAIRBeyond AirN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFEMYFemasys0.030.890.41LYRALyra TherapeuticsN/A2.782.78VTAKCatheter Precision0.190.440.43XAIRBeyond Air0.923.242.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFEMYFemasys65.27%LYRALyra Therapeutics95.62%VTAKCatheter Precision20.34%XAIRBeyond Air31.50%Insider OwnershipCompanyInsider OwnershipFEMYFemasys11.54%LYRALyra Therapeutics3.25%VTAKCatheter Precision2.95%XAIRBeyond Air19.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFEMYFemasys3032.58 million28.82 millionNot OptionableLYRALyra Therapeutics501.64 million1.59 millionOptionableVTAKCatheter Precision141.49 million1.44 millionN/AXAIRBeyond Air705.23 million4.21 millionOptionableVTAK, LYRA, XAIR, and FEMY HeadlinesRecent News About These CompaniesBeyond Air Announces New Warrant AgreementSeptember 11 at 11:27 PM | msn.comBeyond Air, Inc. Announces Exercise of Warrants to Raise $3.25 Million for Clinical Programs and OperationsSeptember 8, 2025 | quiverquant.comQBeyond Air Announces Exercise of Warrants for $3.25 Million of Gross ProceedsSeptember 8, 2025 | globenewswire.comNeuroNOS Granted FDA Orphan Drug Designation for Glioblastoma, the Most Common and Deadliest Primary Malignant Brain Cancer in AdultsSeptember 8, 2025 | markets.businessinsider.comBeyond Air subsidiary granted orphan designation for malignant glioma treatmentSeptember 3, 2025 | msn.comBeyond Air, Inc. CEO Steve Lisi to Participate in H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | quiverquant.comQBeyond Air to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 3, 2025 | globenewswire.comBeyond Air, Inc. Expands Global LungFit® PH Distribution Network to 34 CountriesAugust 20, 2025 | quiverquant.comQBeyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in JapanAugust 20, 2025 | globenewswire.comBeyond Air price target lowered to $5 from $20 at Piper SandlerAugust 14, 2025 | msn.comBeyond Air’s Earnings Call Highlights Growth and ChallengesAugust 13, 2025 | msn.comBeyond Air, Inc. (NASDAQ:XAIR) Q1 2026 Earnings Call TranscriptAugust 13, 2025 | msn.comBeyond Air Reports Strong Revenue Growth in Q1 2026August 13, 2025 | msn.comBeyond Air reports Q1 EPS ($1.53) vs. ($5.32) last yearAugust 12, 2025 | msn.comBeyond Air, Inc. (XAIR) Q1 2026 Earnings Call TranscriptAugust 12, 2025 | seekingalpha.comBeyond Air, Inc. (XAIR) Reports Q1 Loss, Lags Revenue EstimatesAugust 12, 2025 | zacks.comBeyond Air Inc (XAIR) Q1 2026 Earnings Report Preview: What To ExpectAugust 12, 2025 | finance.yahoo.comBeyond Air Schedules First Fiscal Quarter 2026 Financial Results Conference Call and WebcastJuly 25, 2025 | globenewswire.comBeyond Air stock surges after securing Premier group purchasing dealJuly 22, 2025 | in.investing.comBeyond Air Awarded Therapeutic Gases Agreement with Premier, Inc.July 22, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVTAK, LYRA, XAIR, and FEMY Company DescriptionsFemasys NASDAQ:FEMY$0.39 +0.03 (+6.84%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.39 0.00 (-0.54%) As of 09/12/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.Lyra Therapeutics NASDAQ:LYRA$6.29 -0.04 (-0.63%) Closing price 09/12/2025 03:59 PM EasternExtended Trading$6.59 +0.30 (+4.77%) As of 09/12/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Catheter Precision NYSEAMERICAN:VTAK$2.45 -0.05 (-2.00%) Closing price 09/12/2025 04:10 PM EasternExtended Trading$2.52 +0.06 (+2.65%) As of 09/12/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device that temporarily secure sutures and aid clinicians in locating and removing sutures; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company sells it products through distribution partners, independent sales agents, and direct employees. Catheter Precision, Inc. is based in Fort Mill, South Carolina.Beyond Air NASDAQ:XAIR$2.43 +0.17 (+7.52%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.42 -0.01 (-0.21%) As of 09/12/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
